<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01683552</url>
  </required_header>
  <id_info>
    <org_study_id>Aprepitant-Itch</org_study_id>
    <nct_id>NCT01683552</nct_id>
  </id_info>
  <brief_title>Aprepitant in the Management of Biological Therapies-related Severe Pruritus</brief_title>
  <acronym>AprepIt</acronym>
  <official_title>Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Itch is a common side effect of anti-epidermal growth factor receptor antibodies and tyrosine
      kinase inhibitors. Investigators designed a pilot single-center phase II study evaluating the
      effects of Aprepitant, a neurokinin receptor inhibitor, in managing biological
      therapy-induced pruritus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators enroll patients affected by solid tumors which present itch refractory to
      standard treatment (&quot;refractory group&quot;) and patients who did not receive any treatment for
      pruritus (&quot;naïve group&quot;). The intensity of itch will be evaluated with Visual Analogue Scale
      (VAS) score. In the refractory group Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on
      day 5) will be administered after at least 1 week of standard systemic treatment. In the
      naïve group, Aprepitant will be administered after the first onset of severe pruritus. The
      primary end point is to evaluate the effect of aprepitant in managing pruritus both in naive
      and refractory group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of ITCH</measure>
    <time_frame>once before aprepitant administration; 7 days after the first dose of aprepitant, and once a week until the end of biological therapy</time_frame>
    <description>Patients is asked to grade the intensity of their itch on the VAS, with the strongest possible itch marked at the right end of the line (10) and no itch marked at the left end (0). The VAS score is registered in a diary supplied 7 days before starting the study and every week throughout the study period.
Pruritus intensity is evaluated by VAS score once before Aprepitant administration, once 7 days after the first dose of Aprepitant and once a week until the end of biological therapy or the pruritus recurrence. Response (evaluated one week after the first Aprepitant dose) is defined as &gt; 50% reduction of pruritus intensity compared to the baseline value.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>ITCH</condition>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant after anti-itch standard therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>125 mg on day 1; 80 mg on day 3; 80 mg on day 5</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_label>Aprepitant after anti-itch standard therapy</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),</description>
    <arm_group_label>Aprepitant after anti-itch standard therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)</description>
    <arm_group_label>Aprepitant after anti-itch standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed diagnosis of solid tumor

          -  treatment with anti-EGFR antibodies or TKIs

          -  first onset of severe pruritus during treatment (≥7 on Visual Analogue Scale (VAS)
             score)

        Exclusion Criteria:

          -  oral treatment with antimycotics during 4 weeks preceding enrolment

          -  topical treatment during the previous 2 weeks

          -  concomitant,chronic renal or hepatic insufficiency , skin infection or dermatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniele Santini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Campus Bio-Medico of Rome University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campus Bio-Medico of Rome University</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2012</study_first_submitted>
  <study_first_submitted_qc>September 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2012</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Daniele Santini</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ITCH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

